» Articles » PMID: 36271963

Challenges in Osteoporosis Treatment Initiation in Geriatric Patients Admitted Under the Hip-fracture Pathway

Overview
Journal Arch Osteoporos
Publisher Springer
Date 2022 Oct 22
PMID 36271963
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Osteoporosis represents a growing healthcare problem which is often overlooked by healthcare providers and untreated especially in older people. This study aims to assess the rate of osteoporosis treatment initiation and to investigate underlying physician and system-related barriers in geriatric patients admitted for hip fracture.

Methods: A retrospective study was conducted on patients aged 60 years and older, admitted under the hip-fracture pathway from January 2019 to December 2019. Data collected included demographics, co-morbid conditions and laboratory data. Clinical charts were reviewed for whether bone mineral density (BMD) scan has been ordered, plans for bone health were made and reflected in the discharge summary, and if appropriate memos were written. The primary outcome was the prescription of osteoporosis treatment medications. Prescription lists were also reviewed for prescribing patterns of calcium and vitamin D.

Results: A total of 375 patients older than 60 years old were identified. 281 patients who fit the inclusion and exclusion criteria with complete data were further analysed. Within 1 year of hip fracture admission, 63 (22.4%) of them were prescribed with osteoporosis treatment. Multivariate logistic regression identified milder stage of CKD (p = 0.038, OR = 0.617, 95% CI 0.392-0.973) and BMD scan performed (p < 0.001, OR = 6.515, 95% CI 3.180-13.348) as independent factors associated with the prescription of osteoporosis treatment within 1 year of hip fracture admission.

Conclusion: The rate of osteoporosis treatment initiation post-hip fracture is low. Systematic solutions will need to be established to ensure that osteoporosis treatment is addressed prior to discharge.

Citing Articles

The Management of Osteoporosis in Chronic Kidney Disease: A Review of Diagnostic and Therapeutic Approaches.

Tariq F, Ahmad M, Subhan M, Zaid Alvi S, Tariq M, Ullah S Cureus. 2024; 16(11):e73882.

PMID: 39697967 PMC: 11653039. DOI: 10.7759/cureus.73882.


Duration of osteoporosis treatment to reduce the risk of subsequent osteoporotic fracture and all-cause mortality in elderly hip fracture patients in a Korean real-world study.

Lee S, Cho M, Lee H, Lim H, Lee J Arch Osteoporos. 2024; 19(1):9.

PMID: 38198067 PMC: 10781800. DOI: 10.1007/s11657-024-01366-7.

References
1.
Sozen T, Ozisik L, Calik Basaran N . An overview and management of osteoporosis. Eur J Rheumatol. 2017; 4(1):46-56. PMC: 5335887. DOI: 10.5152/eurjrheum.2016.048. View

2.
Gardner M, Flik K, Mooar P, Lane J . Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am. 2002; 84(8):1342-8. DOI: 10.2106/00004623-200208000-00008. View

3.
Teng G, Curtis J, Saag K . Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job?. Curr Osteoporos Rep. 2009; 7(1):27-34. DOI: 10.1007/s11914-009-0006-3. View

4.
Lisk R, Yeong K . Reducing mortality from hip fractures: a systematic quality improvement programme. BMJ Qual Improv Rep. 2016; 3(1). PMC: 4949608. DOI: 10.1136/bmjquality.u205006.w2103. View

5.
Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View